HLB Pharmaceutical Cash And Equivalents vs. EBITDA
| 047920 Stock | KRW 22,250 250.00 1.11% |
For HLB Pharmaceutical profitability analysis, we use financial ratios and fundamental drivers that measure the ability of HLB Pharmaceutical to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well HLB Pharmaceutical Co utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between HLB Pharmaceutical's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of HLB Pharmaceutical Co over time as well as its relative position and ranking within its peers.
HLB |
HLB Pharmaceutical EBITDA vs. Cash And Equivalents Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining HLB Pharmaceutical's current stock value. Our valuation model uses many indicators to compare HLB Pharmaceutical value to that of its competitors to determine the firm's financial worth. HLB Pharmaceutical Co is rated below average in cash and equivalents category among its peers. It is rated fourth in ebitda category among its peers totaling about 0.46 of EBITDA per Cash And Equivalents. The ratio of Cash And Equivalents to EBITDA for HLB Pharmaceutical Co is roughly 2.15 . Comparative valuation analysis is a catch-all model that can be used if you cannot value HLB Pharmaceutical by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for HLB Pharmaceutical's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.HLB EBITDA vs. Cash And Equivalents
Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
HLB Pharmaceutical |
| = | 6.64 B |
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
HLB Pharmaceutical |
| = | 3.08 B |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
HLB EBITDA Comparison
HLB Pharmaceutical is currently under evaluation in ebitda category among its peers.
HLB Pharmaceutical Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in HLB Pharmaceutical, profitability is also one of the essential criteria for including it into their portfolios because, without profit, HLB Pharmaceutical will eventually generate negative long term returns. The profitability progress is the general direction of HLB Pharmaceutical's change in net profit over the period of time. It can combine multiple indicators of HLB Pharmaceutical, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
HLB Pharmaceutical Co., Ltd, a pharmaceutical company, develops peptide drugs in South Korea. HLB Pharmaceutical Co., Ltd was founded in 1998 and is headquartered in Namyangju, South Korea. HLBPHARMA is traded on Korean Securities Dealers Automated Quotations in South Korea.
HLB Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on HLB Pharmaceutical. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of HLB Pharmaceutical position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the HLB Pharmaceutical's important profitability drivers and their relationship over time.
Use HLB Pharmaceutical in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if HLB Pharmaceutical position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in HLB Pharmaceutical will appreciate offsetting losses from the drop in the long position's value.HLB Pharmaceutical Pair Trading
HLB Pharmaceutical Co Pair Trading Analysis
The ability to find closely correlated positions to HLB Pharmaceutical could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace HLB Pharmaceutical when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back HLB Pharmaceutical - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling HLB Pharmaceutical Co to buy it.
The correlation of HLB Pharmaceutical is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as HLB Pharmaceutical moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if HLB Pharmaceutical moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for HLB Pharmaceutical can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your HLB Pharmaceutical position
In addition to having HLB Pharmaceutical in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Mid Cap ETFs Thematic Idea Now
Mid Cap ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Mid Cap ETFs theme has 70 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Mid Cap ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in HLB Stock
To fully project HLB Pharmaceutical's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of HLB Pharmaceutical at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include HLB Pharmaceutical's income statement, its balance sheet, and the statement of cash flows.